MAPT and amyloidosis: Generally, evidence from epidemiology, neuroimaging, and biomarker studies suggests that sustained normal leptin signaling from midlife may reduce AD risk by limiting amyloid and tau pathology, preserving synapses, and reducing neuroinflammation [308].